3B Blackbio DX Ltd
3B Blackbio DX Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #33 of 33 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Company expects an overall growth rate of 10% to 15% in topline (sales/revenue) for the current year. 3B BlackBio DX Limited expects overall revenue growth of 10% to 15% for the full year FY26.
From 3B Blackbio DX Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Company expects an overall growth rate of 10% to 15% in topline (sales/revenue) for the current year.
- Exports are expected to grow higher, between 15% to 20%.
- Post seasonal spikes, organic growth in domestic business is around 11.4% to 20%.
- Future growth drivers include launch of new products, ongoing contract supplies (e.g., HAT contract till 2027), and expanding exports to 70 countries.
- Molecular diagnostic market is nascent in India, providing room for growth.
- Company targets EBITDA positive transition for Coris acquisition by next year, signaling revenue growth.
- Growth in exports by TRUPCR Europe is strong, at 20% plus.
- New product developments like sample-to-answer system and automated extraction kits expected to further aid growth.
2 more points from 3B Blackbio DX Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has allocated around INR 50 crore as reserve for the company itself.
- Approximately INR 130-140 crore is targeted for acquisitions, with active scouting underway.
- Two consultants have been appointed to identify acquisition opportunities.
- The focus is on acquiring companies to drive growth, with dedicated management time spent on scouting.
- Investment is also being made in product development, including sample-to-answer systems and automated extraction kits.
2 more points from 3B Blackbio DX Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a significant order from the HAT contract worth USD 6 million to be supplied over four years, with an expected annual revenue of approximately USD 1.5 million until the contract is completed.
- For the current year, INR 8.8 crores (~USD 1.18 million) from the HAT contract was recognized as revenue, which is considered a one-off event but recurring annually until the contract ends.
- The HAT contract is expected to continue supplying for the next two years at around USD 1.5 million per year.
2 more points from 3B Blackbio DX Ltd's call on order book
Create a free account to keep reading this call
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre Ltd (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality Care Ltd (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthcare Ltd (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare Ltd (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q3 FY26 results?
Company expects an overall growth rate of 10% to 15% in topline (sales/revenue) for the current year. 3B BlackBio DX Limited expects overall revenue growth of 10% to 15% for the full year FY26.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 17.7 with a market cap of ₹1,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company has allocated around INR 50 crore as reserve for the company itself.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.